← Eichor
Study identifier: NCT06444880 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

Condition: SMARCB1-Deficient Malignancies · Epithelioid Sarcoma · Renal Medullary Carcinoma  ·  Sponsor: M.D. Anderson Cancer Center

PhasePhase 2
Planned participants40
Who can joinAll sexes, 12 Years to no upper limit
Healthy volunteersNo

About this study

To find out if ubamatamab, given by itself or in combination with cemiplimab, can help to control the disease in participants with renal medullary carcinoma (RMC) and epithelioid sarcoma (ES).

This description comes directly from the study's public registry record.

Talk to the study team

Pavlos Msaouel, MD,PHD,PHD  ·  (713) 563-4585  ·  pmsaouel@mdanderson.org

Always discuss trial participation with your own doctor first.

Locations (1)

MD Anderson Cancer CenterHouston, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06444880